Shares of Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) have been assigned an average broker rating score of 1.13 (Strong Buy) from the four analysts that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a buy recommendation and three have assigned a strong buy recommendation to the company.

Analysts have set a 1 year consensus price target of $27.00 for the company, according to Zacks. Zacks has also given Clementia Pharmaceuticals an industry rank of 100 out of 265 based on the ratings given to its competitors.

Several equities research analysts have recently weighed in on CMTA shares. Morgan Stanley started coverage on shares of Clementia Pharmaceuticals in a research note on Monday, August 28th. They set an “overweight” rating and a $27.00 target price for the company. BTIG Research started coverage on shares of Clementia Pharmaceuticals in a research note on Thursday, August 31st. They set a “buy” rating and a $32.00 target price for the company. Leerink Swann started coverage on shares of Clementia Pharmaceuticals in a research note on Monday, August 28th. They set an “outperform” rating and a $23.00 target price for the company. Finally, Wedbush started coverage on shares of Clementia Pharmaceuticals in a research note on Monday, August 28th. They set an “outperform” rating and a $26.00 target price for the company.

Shares of Clementia Pharmaceuticals (CMTA) traded down $0.76 during mid-day trading on Monday, hitting $16.01. The company’s stock had a trading volume of 51,479 shares, compared to its average volume of 98,342. Clementia Pharmaceuticals has a 12 month low of $15.05 and a 12 month high of $18.95.

Institutional investors and hedge funds have recently made changes to their positions in the company. Birchview Capital LP acquired a new stake in shares of Clementia Pharmaceuticals during the third quarter worth about $372,000. Point72 Asset Management L.P. acquired a new stake in shares of Clementia Pharmaceuticals during the third quarter worth about $506,000. Sectoral Asset Management Inc acquired a new stake in shares of Clementia Pharmaceuticals during the third quarter worth about $512,000. Victory Capital Management Inc. acquired a new stake in Clementia Pharmaceuticals in the third quarter valued at about $520,000. Finally, Susquehanna International Group LLP acquired a new stake in Clementia Pharmaceuticals in the third quarter valued at about $729,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

WARNING: This news story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another domain, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/11/zacks-clementia-pharmaceuticals-inc-cmta-given-27-00-average-target-price-by-analysts-2.html.

About Clementia Pharmaceuticals

Clementia Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Its lead product candidate, palovarotene, is an oral small molecule that binds and activates retinoic acid receptor gamma (an RARg agonist), and has activity in preventing abnormal new bone formation as well as scar tissue formation (or fibrosis) in a variety of tissues in animal models.

Get a free copy of the Zacks research report on Clementia Pharmaceuticals (CMTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Clementia Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.